Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer (Q46205657)

20 December 2017

title

Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer (English)

1 reference

20 December 2017

author name string

M-O Timsit

series ordinal

1

1 reference

20 December 2017

T Lebret

series ordinal

2

1 reference

20 December 2017

A Méjean

series ordinal

3

1 reference

20 December 2017

language of work or name

French

0 references

publication date

1 November 2008

1 reference

20 December 2017

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

published in

1 reference

20 December 2017

volume

18 Suppl 7

1 reference

20 December 2017

page(s)

S365-75

1 reference

20 December 2017

American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

The natural history of androgen independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Microtubules as a target for anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Chemotherapy for the treatment of hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Phase II Evaluation of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Patients with Hormone-Sensitive Prostate Adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Vitamin D and the epidemiology of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974568-8

7 January 2021

10.1016/S1166-7087(08)74568-8

Identifiers

DOI

1 reference

20 December 2017

PubMed ID

19070817

1 reference

20 December 2017